AI Article Synopsis

  • This study explored how patients with refractory Mycobacterium avium complex lung disease manage adverse events related to amikacin liposome inhalation suspension (ALIS) through semi-structured interviews.
  • Twenty patients participated, sharing a total of 44 unique strategies to tackle treatment-related adverse events, which fell into three main categories: preparation for treatment, prevention of increased AEs, and ways to persist in treatment despite these events.
  • The study found that common strategies included utilizing educational materials, managing throat irritation, and addressing fatigue, with evidence suggesting that the range of strategies identified was comprehensive for the patient population.

Article Abstract

Introduction: This study aimed to gain insight from patients with refractory Mycobacterium avium complex lung disease (MAC-LD) into strategies used to manage adverse events (AEs) associated with amikacin liposome inhalation suspension (ALIS).

Methods: We conducted semi-structured interviews with US patients with refractory MAC-LD prescribed ALIS in a real-world setting. Interview transcripts were analyzed and coded to identify patterns in participants' descriptions of their ALIS treatment experiences, including AEs and their disruptiveness, and AE mitigation strategies, including participants' ratings of strategies' effectiveness. Concept saturation was also assessed.

Results: Twenty participants (mean age 48.7 years; 80% women; mean ALIS duration 5.45 months) were interviewed. At the time of the interview, 15 participants (75%) had received ALIS for > 1 month and 13 (65%) were currently receiving ALIS. Participants described 44 unique AE mitigation strategies, which can be categorized into three groups: prepare for treatment; prevent increased emergence of AEs; and persist on treatment by mitigating AEs. Common strategies (reported by ≥ 50% of participants) included use of educational materials from the patient support program, localized management of throat irritation, and symptom management to reduce fatigue. Evidence of concept saturation was observed: no new strategies were identified in the last five interviews, which suggests the sample was robust enough to identify all mitigation strategies likely to be used by the broader patient population.

Conclusions: This real-world study identified a diverse set of potential AE mitigation strategies intended to help individual patients prepare for ALIS treatment, prevent the increased emergence of certain AEs, and mitigate the impact of AEs on treatment persistence. Developing a comprehensive accounting of the types of mitigation strategies in use among patients in real-world settings can inform future investigation of the effectiveness of such strategies, and support evidence-based recommendations for treatment management.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11339226PMC
http://dx.doi.org/10.1007/s41030-024-00263-1DOI Listing

Publication Analysis

Top Keywords

mitigation strategies
24
strategies
10
amikacin liposome
8
liposome inhalation
8
inhalation suspension
8
patients refractory
8
alis treatment
8
concept saturation
8
treatment prevent
8
prevent increased
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!